Q3 2025 Merck KGaA Earnings Call Transcript
Key Points
- Merck KGaA (MKGAF) reported solid organic growth across all three sectors, with group revenues increasing by 5.2% and EBITDA pre rising by 8.8%.
- Life Science delivered the strongest organic sales growth at 6%, driven by the Process Solutions business, which showed organic growth above 10% for the third consecutive quarter.
- The Healthcare sector saw organic growth of 4.6%, largely driven by the CM&E franchise and strong performance from Mavenclad, which achieved double-digit growth.
- Electronics experienced organic growth of 5%, supported by the semi-material business, and the successful divestment of Surface Solutions is expected to enhance margins.
- Merck KGaA (MKGAF) successfully issued a US dollar bond, which was over four times oversubscribed, demonstrating strong investor confidence and further diversifying its fixed income investor base.
- Currency fluctuations negatively impacted all sectors, with FX headwinds amounting to minus EUR256 million.
- The Healthcare sector faced competitive headwinds, particularly in oncology, with rising competition for Erbitux in China.
- The Mavenclad US patent ruling could lead to earlier-than-expected generic competition, impacting future sales and earnings projections.
- Electronics' DS&S sales were down in the low teens range, and the sector is expected to face a muted year in 2025.
- The US government shutdown and challenging market conditions in China continue to pose headwinds for the Science & Lab Solutions segment.
Dear ladies and gentlemen, welcome to the Merck investor and analyst conference call on third quarter 2025. (Operator Instructions) Please note this is our customers' request, this conference will be recorded. I'm now handing over to Florian Schraeder, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.
Thank you so much, Sarah and a sincere welcome to everyone joining the Merck Q3 '25 results call. I'm Florian Schraeder, the Head of Investor Relations at Merck. I'm delighted to be here today with Belen Garijo, our Group CEO; and Helene von Roeder, our Group CFO.
During the Q&A part of this call, we will also be joined by Kai Beckmann, CEO of Electronics and Deputy Chair of the Executive Board; Jean-Charles Wirth, CEO of Life Science; and Danny Bar-Zohar, CEO of Healthcare. In the first few minutes, we will walk you through the key slides of our presentation. After that, we will be happy to take your questions.
Now I will turn it over to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
